| Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis C Molinelli, F Jacobs, E Agostinetto, G Nader-Marta, M Ceppi, ... ESMO open 8 (4), 101592, 2023 | 21 | 2023 |
| HER2-low breast cancer: where are we? C Molinelli, F Jacobs, C Marchiò, F Pitto, M Cosso, S Spinaci, ... Breast Care 17 (6), 533-545, 2022 | 20 | 2022 |
| Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients D Gentile, A Sagona, C De Carlo, B Fernandes, E Barbieri, SDM Grimaldi, ... The Breast 69, 323-329, 2023 | 14 | 2023 |
| Sentinel lymph node biopsy in breast cancer patients undergoing neo-adjuvant chemotherapy: clinical experience with node-negative and node-positive disease prior to systemic … C Tinterri, A Sagona, E Barbieri, S Di Maria Grimaldi, G Caraceni, ... Cancers 15 (6), 1719, 2023 | 12 | 2023 |
| Opportunities and challenges of synthetic data generation in oncology F Jacobs, S D'Amico, C Benvenuti, M Gaudio, G Saltalamacchia, ... JCO Clinical Cancer Informatics 7, e2300045, 2023 | 9 | 2023 |
| Hope and hype around immunotherapy in triple-negative breast cancer F Jacobs, E Agostinetto, C Miggiano, R De Sanctis, A Zambelli, A Santoro Cancers 15 (11), 2933, 2023 | 9 | 2023 |
| Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors E Zattarin, D Presti, L Mariani, C Sposetti, R Leporati, A Menichetti, C Corti, ... NPJ breast cancer 9 (1), 27, 2023 | 9 | 2023 |
| Unlocking the potential of circulating miRNAs in the breast cancer neoadjuvant setting: a systematic review and meta-analysis P Tiberio, M Gaudio, S Belloni, S Pindilli, C Benvenuti, F Jacobs, ... Cancers 15 (13), 3424, 2023 | 7 | 2023 |
| The Relationship among Bowel [18] F-FDG PET Uptake, Pathological Complete Response, and Eating Habits in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy P Tiberio, L Antunovic, M Gaudio, A Viganò, M Pastore, C Miggiano, ... Nutrients 15 (1), 211, 2023 | 7 | 2023 |
| Loco-regional treatment of the primary tumor in de novo metastatic breast cancer patients undergoing front-line chemotherapy C Tinterri, A Sagona, E Barbieri, S Di Maria Grimaldi, F Jacobs, ... Cancers 14 (24), 6237, 2022 | 6 | 2022 |
| Sticking to the rules: outcome and success rate of guideline-based diarrhea management in metastatic breast cancer patients treated with abemaciclib F Jacobs, E Agostinetto, A Solferino, R Torrisi, G Masci, A Santoro, ... Journal of Clinical Medicine 12 (5), 1775, 2023 | 5 | 2023 |
| Post-neoadjuvant treatment strategies for patients with early breast cancer E Agostinetto, F Jacobs, V Debien, A De Caluwé, CF Pop, X Catteau, ... Cancers 14 (21), 5467, 2022 | 5 | 2022 |
| From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds R De Sanctis, F Jacobs, C Benvenuti, M Gaudio, R Franceschini, ... Frontiers in Pharmacology 13, 909566, 2022 | 5 | 2022 |
| Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions R Gerosa, R De Sanctis, F Jacobs, C Benvenuti, M Gaudio, ... Critical Reviews in Oncology/Hematology, 104324, 2024 | 4 | 2024 |
| The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy C Tinterri, B Fernandes, A Zambelli, A Sagona, E Barbieri, ... Cancers 16 (2), 376, 2024 | 4 | 2024 |
| Clinical review on the management of breast cancer visceral crisis C Benvenuti, M Gaudio, F Jacobs, G Saltalamacchia, R De Sanctis, ... Biomedicines 11 (4), 1083, 2023 | 4 | 2023 |
| Potential role of circulating miRNAs for breast cancer management in the neoadjuvant setting: A road to pave C Benvenuti, P Tiberio, M Gaudio, F Jacobs, G Saltalamacchia, S Pindilli, ... Cancers 15 (5), 1410, 2023 | 4 | 2023 |
| Ovarian suppression: early menopause and late effects C Molinelli, F Jacobs, G Nader-Marta, R Borea, G Scavone, S Ottonello, ... Current Treatment Options in Oncology 25 (4), 523-542, 2024 | 3 | 2024 |
| Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab V Debien, GN Marta, E Agostinetto, M Sirico, F Jacobs, C Molinelli, ... Critical reviews in oncology/hematology, 104089, 2023 | 3 | 2023 |
| HR+/HER2− de novo metastatic breast cancer: a true peculiar entity? R Torrisi, F Jacobs, C Miggiano, R De Sanctis, A Santoro Drugs in Context 12, 2023 | 3 | 2023 |
